IGF1R and breast cancer: In this study, Yang and colleagues also demonstrated that silencing CXCL1 or blocking IGF1R/STAT3 signaling disrupts this HMGB1–autophagy–MRPs axis and restores drug sensitivity in breast cancer [137].